*SCALPSWINGSTRADDLE*

[ADVFN_bioking]

EVOK = Price:$1.05 --Market Cap $26 M --NDA resubmission during the Quarter -- Drug targeting $3+ BILLION market = Potential 5+BAGGER

Evoke Pharma (EVOK)

Market-Cap: $26 Million
Cash: $6.5 Million (additional ~$5 million available via ATM)
Price: $1.05

Shares Out: 24.1 Million


Presentation
https://evokepharmainc.gcs-web.com/static-files/0f21016a-d472-4005-a293-dd8d02a857e7


•Gimoti™: Novel nasal delivery of metoclopramide for the symptomatic relief of acute and recurrent diabetic gastroparesis in women

•Large market opportunity:~12-16M patients with symptoms (80% women); ~2-3M currently treated in US given limited efficacy from few available treatment options

•Only one FDA-approved therapy for gastroparesis: Metoclopramide (oral & IV) still has ~4M prescriptions of the oral medication prescribed annually

•Positive data from pivotal comparative exposure PK study: Gimoti demonstrated AUC equivalence

•Estimated $3-4B prescription market

•Resubmission of 505(b)(2) NDA expected Q4 2019

If approved, Gimoti would be the first non-oral pharmacotherapy for gastroparesis approved in 40 years; metoclopramide is currently available in oral and injectable formulations.